The Lyme disease vaccine: Conception, development, and implementation

Annals of Internal Medicine

Volumn 132, Issue 8, 2000, Pages 661-668

  Thanassi, Wendy Todaro ^a   Schoen, Robert T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYME DISEASE VACCINE; OUTER MEMBRANE PROTEIN;

ARTHRALGIA; BORRELIA BURGDORFERI; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG INDICATION; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; INFECTION RISK; LYME DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TICK; VACCINATION; VACCINE PRODUCTION;

EID: 0034681975     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-8-200004180-00009     Document Type: Review

References (74)

1. Afzelius A. Verhandlungen der dermatologischen. Archiv fur Dermatologie und Syphilis. 1910;101:405-6.
2. Steere AC, Malawista SE, Snydman DR, Shope RE, Andiman WA, Steele FM. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults m three Connecticut communities. Arthritis Rheum. 1977;20:7-17.
3. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease - a tick-borne spirochetosis? Science. 1982;216:1317-9.
4. Matuschka FR, Ohlenbusch A, Eiffert H, Richter D, Spielman A. Characteristics of Lyme disease spirochetes in archived European ticks. J Infect Dis. 1996;174:424-6.
5. Summary of notifiable diseases. United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;45:1-87.
6. Wallich R, Kramer MD, Simon MM. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine. Infection. 1996; 24:396-7.
7. Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther. 1998;20:993-1008.
8. Busch U, Hizo-Teufel C, Boehmer R, Fingerle V, Nitschko H, Wilske B, et al. Three species of Borrelia burgdorferi sensu lato (B. burgdorieri sensu stricto, B. afzelii, and B. garinii) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis and PCR. J Clin Microbiol. 1996;34:1072-8.
9. Barbour AG, Maupin GO, Teltow GJ, Carter G, Piesman J. Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. J Infect Dis. 1996;173:403-9.
10. Edelman R. Perspective on the development of vaccines against Lyme disease. Vaccine. 1991;9:531-2.
11. Tsai TF, Bailey RE, Moore PS. National surveillance of Lyme disease, 1987-1988. Conn Med. 1989;53:324-6.
12. Young JD. Underreporting of Lyme disease [Letter]. N Engl J Med. 1998;338: 1629.
13. Evans JB. Lyme disease. Curr Opin Rheumatol. 1996;8:327-33.
14. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987;107:725-31.
15. Seiler KP, Weiss JJ. Immunity to Lyme disease: protection, pathology and persistence. Curr Opin Immunol. 1996;8:503-9.
16. Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun. 1993;61:2774-9.
17. Lengl-Janssen B, Strauss AF, Steere AC, Kamradt T, The T helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J Exp Med. 1994;180:2069-78.
18. Lyme disease: Connecticut. Southern Connecticut Department of Health. Connecticut Epidemiology. 1995;15:13-6.
19. Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope. 1985;95:1341-5.
20. Dotevall L, Rosengren LE, Hagberg L. Increased cerebrospinal fluid levels of glial fibrillary acidic protein (GFAp) in Lyme neuroborreliosis. Infection. 1996;24:125-9.
21. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, DeSanna ET, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med. 1983;99:22-6.
22. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, et al. Treatment of early Lyme disease. Am J Med. 1992;92:396-403.
23. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxicillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990;336:1404-6.
24. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetii and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992;117:273-80.
25. Telford SR 3d, Dawson JE, Katavolos P, Warner CK, Kolbert CP, Persing DH. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle Proc Nat Acad Sci U S A. 1996;93:6209-14.
26. Lane RS, Quistad GB. Borreliacidal factor in the blood of the western fence lizard (Sceloporus occidentalis). J Parasitol. 1998;84:29-34.
27. Shapiro ED, Gerber MA, Holabird NB, Berg AT, Feder HM Jr, Bell GL, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med. 1992;327:1769-73.
28. Warshafsky S, Nowakowski J, Nadelman RB, Kamer RS, Peterson SJ, Wormser GP, et al. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. J Gen Intern Med. 1996;11:329-33.
29. Johnson RC, Kodner C, Russell M. Passive immunization of hamsters against experimental infection with the Lyme disease spirochete. Infect Immun. 1986;53:713-4.
30. Johnson RC, Kodner C, Russell M. Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun. 1986; 54:897-8.
31. Lissman BA, Bosler EM, Camay H, Ormiston BG, Benach JL. Spirochete-associated arthritis (Lyme disease) in a dog. J Am Vet Med Assoc. 1984;185: 219-20.
32. Chu HJ, Chavez LG Jr, Blumer BM, Sebring RW, Wasmoen TL, Acree WM. Immunogenicity and efficacy study of commercial Borrelia burgdorferi bacterm. J Am Vet Med Assoc. 1992;201:403-11.
33. Sigal LH. Cross-reactivity between Borrelia burgdorferi flagellin and a human axonal 64,000 molecular weight protein. J Infect Dis. 1993;167:1372-8.
34. Aberer E, Brunner C, Suchanek G, Klade H, Barbour A, Stanek G, et al. Molecular mimicry and Lyme borreliosis: a shared antigenic determinant between Borrelia burgdorferi and human tissue. Ann Neurol. 1989;26:732-7.
35. Steere AC. Lyme disease. N Engl J Med. 1989;321:586-96.
36. Pham TN, Koide S. NMR studies of Borrelia burgdorferi OspA, a 28kDa protein containing a single-layer beta-sheet. J Biomol NMR. 1998;11:407-14.
37. Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease: appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J Clin Invest. 1986;78:934-9.
38. Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, et al. Genomic sequence of a Lyme disease spirochete, Borrelia burgdorferi. Nature. 1997;390:580-6.
39. Barthold SW, Persing DH, Armstrong AL, Peeples RA. Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice. Am J Pathol. 1991;139:263-73.
40. Szczepanski A, Benach JL. Lyme borreliosis: host responses to Borrelia burgdorferi. Microbiol Rev. 1991;55:21-34.
41. Aydintug MK, Gu Y, Philipp MT. Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey. Infect Immun. 1994;62:4929-37.
42. Greene RT, Walker RL, Nicholson WL, Heidner HW, Levine JF, Burgess EC, et al. Immunoblot analysis of immunoglobulin G response to the Lyme disease agent (Borrelia burgdorferi) in experimentally and naturally infected dogs. J Clin Microbiol. 1988;26:648-53.
43. Gern L, Schaible UE, Simon MM. Mode of inoculation of lhe Lyme disease agent Borrelia burgdorferi influences infection and immune responses in inbred strains of mice. J Infect Dis. 1993;167:971-5.
44. Roehrig JT, Piesman J, Hunt AR, Keen MG, Happ CM, Johnson BJ. The hamster immune response to tick-transmitted Borrelia burgdorferi differs from the response to needle-inoculated, cultured organisms. J Immunol. 1992;149: 3648-53.
45. Barthold SW, Fikrig E, Bockenstedt LK, Persing DH. Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect Immun. 1995;63:2255-61.
46. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Nat Acad Sci U S A. 1995;92:2909-13.
47. de Silva AM, Telford SR 3d, Brunet LR, Barthold SW, Fikrig E. Borrelia burgdorferi OspA is an arthropod-specific transmission blocking Lyme disease vaccine. J Exp Med. 1995;183:271-5.
48. Barthold SW, Beck DS, Hansen GM, Terwilliger GA, Moody KD. Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis. 1990; 162:133-8.
49. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunizing with recombinant OsaA. Science. 1990;250:553-6.
50. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun. 1992;60: 773-7.
51. Schaible UE, Kramer MD, Eickmann K, Modolell M, Museteanu C, Simon MM. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Nat Acad Sci U S A. 1990;87:3768-72.
52. Lovrich SD, Callister SM, DuChateau BK, Lim LC, Winfrey J, Day SP, et al. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect Immun. 1995;63:2113-9.
53. Chang YF, Appel MJ, Jacobsen RH, Shin SJ, Harpending P, Straubinger R, et al. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immunol. 1995;63:3543-9.
54. Philipp MT, Lobet Y, Bohm RP, Roberts ED, Dennis VA, Gu Y, et al. The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey. Vaccine. 1997;15 1872-87.
55. Pavia CJ, Kissel V, Bittker S, Cabello F, Levine S. Antiborrelial activity of serum from rats injected with the Lyme disease spirochete. J Infect Dis. 1991; 163:656-9.
56. Montgomery RR, Nathanson MH, Malawista SE. Fc-and non-Fc-mediated phagocytosis of Borrelia burgdorferi by macrophages. J Infect Dis. 1994; 170:890-3.
57. Erdile LF, Brandt MA, Warakomski DJ, Westrack GJ, Sadziene A, Barbour AG, et al. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun. 1993;61:81-90.
58. Chamberlain NR, Brandt ME, Erwin AL, Radolf JD, Norgard MV. Major integral membrane protein immunogens of Treponema pallidum are proteolipids. Infect Immun. 1989;57:2872-7.
59. Van Hoecke C, DeGrove D, Hansen P, Lebacq E. Evaluation of three formulations of a candidate vaccine against Lyme disease in healthy adult volunteers [Abstract]. Boiogna, Itay: Sixth International Conference on Lyme Borreliosis; 1994.
60. Marks D, Hosbach P, Koster F, Wormser G, Bryant G, Gwaltney J, et al. Clinical studies in humans of outer surface protein A (OspA) vaccine for Lyme disease [Abstract]. Bologna, Italy: Sixth Internationa Conference on Lyme Borreliosis; 1994.
61. Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA. 1994;271:1764-8.
62. Schoen RT, Meurice F, Brunei CM, Cretella S, Krause DS, Craft JE, et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis. 1995;172:1324-9.
63. Steere AC, Sikand VK, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoorotein A with adjuvant. Lyme Disease Vaccine Study Group N Engl J Med. 1998;339:209-15.
64. Van Hoecke C, Voet P, DeGrove D, Hansen P. Immunogenicity of Al(OH)3-adsorbed and plain hpoprotein OspA vaccine formulations in monkeys and man [Abstract]. Orlando, Florida: 34th Interscience Conference on Antimicrobial Agents Chemotherapy: 1994.
65. Sigal LM, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med. 1998;339:216-22.
66. Parenti D, Gillet M, Sennewald E, Neiss A, Rockhold F, Xie F, et al. Correlate of protection for Lyme disease (LD) using LYMErix Recombinant adjuvanted Borrelia burgdorferi outer surface lipoprotein A(L-OspA) vaccine [Abstract]. Denver, CO: Infectious Diseases Soc of America; 1998:704.
67. Parenti D, Schoen R, Sikand V, Caldwell M, Van Hoecke C, Buscarino C, et al. Evaluation of reactogenicity and immunogenicity of LYMErix, recombmant L-OspA vaccine against Lyme disease, administered on two different schedules [Abstract]. Denver, CO: Infectious Diseases Soc of America; 1998: 705.
68. Van Hoecke C, Lebacq E, Beran J, Parenti D. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin Infect Dis. 1999;28:1260-4.
69. Mathiesen DA, Oliver JH Jr, Kolbert CP, Tullson ED, Johnson BJ, Campbell GL, et al. Genetic heterogeneity of Borrelia burgdorferi in the United States. J Infect Dis. 1997;175:98-107.
70. Vasiliu V, Herzer P, Rossler D, Lehnert G, Wilske B. Heterogeneity of Borrelia burgdorferi sensu lato demonstrated by an ospA-type-specific PCR in synovial fluid from patients with Lyme arthritis. Med Microbiol Immunol (Berl). 1998;187:97-102.
71. Fikrig E, Barthold SW, Persing DH, Sun X, Kantor FS, Flavell RA. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. J Immunol. 1992;148:2256-60.
72. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal WkIy Rep. 1999;48:1-17.
73. Beran J, Van Hoecke C, Boutriau D. Evaluation of an OspA Lyme disease vaccine in children aged 5-1 5 years [Abstract]. Denver, CO: Infectious Disease Soc of America; 1998:75.
74. Lyme disease vaccine. Med Lett Drugs Ther. 1999;41:29-30.